Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
Taysha Gene Therapies, Inc. reported that it issued a press release titled “Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome.” The company states that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for TSHA-102, its investigational therapy for Rett syndrome, and that it has received a positive regulatory update on this program. The full details are provided in the press release attached as Exhibit 99.1.
Taysha Gene Therapies (TSHA) filing a Form 144 notifies the planned sale of 10,770 shares of common stock through Maxim Group on Nasdaq with an aggregate market value of $30,479.10. The shares were acquired and vested as RSU awards on 09/22/2025 and settled in stock as consideration for the reporting person’s service. The filing shows 272,794,885 shares outstanding and reports no other sales in the past three months. The filer certifies no undisclosed material adverse information.
Taysha Gene Therapies, Inc. (TSHA) filing a Form 144 notifies a proposed sale of 200,000 common shares through Jefferies LLC on 09/10/2025 with an aggregate market value of $652,000.00. The filing lists total shares outstanding as 272,794,885. Securities to be sold were acquired via vested awards: 158,850 shares from a 01/02/2024 RSU award and 37,106 plus 4,044 shares from vested option grants on 05/31/2023. The form also discloses a prior sale of 57,054 shares on 08/21/2025 for $162,603.90. Several standard filer and issuer contact fields in the notice are blank or not provided.
Nagendran Sukumar, President and Head of R&D and a director of Taysha Gene Therapies (TSHA), reported the disposition of 57,054 shares of the company's common stock on 08/21/2025. The filing states the shares were sold pursuant to a sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock units, at a weighted-average price of $2.85 per share (individual trades ranged $2.841 to $2.865).
After the sale, the reporting person beneficially owns 1,165,289 shares of common stock, held directly. The Form 4 was signed on 08/22/2025 and contains a standard offer to provide breakouts of the amounts sold at each price upon request.
Taysha Gene Therapies (TSHA) CFO Kamran Alam reported a sale of 54,491 shares on 08/21/2025 at a weighted-average price of $2.85 per share. The filing states the shares were sold pursuant to a "sell-to-cover" arrangement to satisfy income tax liabilities from vested restricted stock units, not an open-market discretionary sale. After the transaction Mr. Alam beneficially owned 1,187,603 shares. The filing is a routine Section 16 Form 4 disclosure documenting insider tax-related share disposals and compliance with reporting requirements.
Taysha Gene Therapies (TSHA) filed a Form 144 reporting a proposed sale of 54,491 shares of common stock (RSU award) on 08/21/2025. The shares were a vested RSU grant settled in stock to the reporting person as consideration for continued employment. The broker listed is Maxim Group LLC and the sale is planned on Nasdaq. The filing shows an aggregate market value of $156,389.17 based on the proposed sale and lists 272,794,885 shares outstanding. The filer reports no other sales in the past three months.
Taysha Gene Therapies insider notice to sell 19,604 shares via Maxim Group under Rule 144. The filing reports a proposed sale of 19,604 shares of common stock with an aggregate market value of $56,263.48 based on the filer’s information. The shares represent vested RSU awards acquired and settled in stock on 08/21/2025; the stated consideration for those awards was the reporting person’s continued service as an employee. The filing lists total outstanding shares of 272,794,885 and identifies Nasdaq as the exchange for the approximate sale date of 08/21/2025. No other sales in the past three months were reported.
Taysha Gene Therapies, Inc. (TSHA) filing a Form 144 notifies the proposed sale of 57,054 shares of common stock through Maxim Group LLC on 08/21/2025 on Nasdaq. The filing shows these shares were acquired the same day as a vested RSU award from the issuer and settled in stock, with the stated consideration being the reporting person’s continued service as an employee. The filing reports no other sales in the past three months and includes the standard representation that the seller has no undisclosed material adverse information about the issuer.
Taysha Gene Therapies (TSHA) filing a Form 144 notifies intent to sell 27,590 shares of common stock through Maxim Group LLC on 08/21/2025 with an aggregate market value of $79,183.30. The shares were acquired as a RSU award and were vested and settled in stock on 08/21/2025, with the stated consideration being the reporting person’s continued service as an employee. The filing reports 272,794,885 shares outstanding and indicates no securities sold by the reporting person in the prior three months.
Taysha Gene Therapies (TSHA) filed a Form 144 reporting a proposed sale of 50,451 shares of common stock, representing a small fraction of the company's outstanding shares. The shares were issued as an RSU award and vested on 08/21/2025, with the reporting person stating the consideration for the grant was continued service as an employee. The proposed sale lists Maxim Group LLC as the broker and an aggregate market value of $144,794.37. The approximate date of sale and the acquisition/settlement date are both reported as 08/21/2025, and the securities are listed on Nasdaq. The filer reports no other securities sold in the past three months and affirms no undisclosed material adverse information.